[Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose].

The clinical use of the angiotensin enzyme converter inhibitors (AECI) has represented one of the main advances in medicine in the last quarter of a century. Assuming the pathogenic pluripotentialness of cardiovascular diseases (arterial hypertension, atherosclerosis, cardiac failure etc.), from the currently available experimental and clinical evidence of these compounds, it may be said that the mechanisms of action of the AECI make them to be the first pharmacologic group in cardiovascular medicine to have true pluripotentialness.